Literature DB >> 32651459

Current trends in gene recovery mediated by the CRISPR-Cas system.

Hyeon-Ki Jang1, Beomjong Song2, Gue-Ho Hwang1, Sangsu Bae3.   

Abstract

The CRISPR-Cas system has undoubtedly revolutionized the genome editing field, enabling targeted gene disruption, regulation, and recovery in a guide RNA-specific manner. In this review, we focus on currently available gene recovery strategies that use CRISPR nucleases, particularly for the treatment of genetic disorders. Through the action of DNA repair mechanisms, CRISPR-mediated DNA cleavage at a genomic target can shift the reading frame to correct abnormal frameshifts, whereas DNA cleavage at two sites, which can induce large deletions or inversions, can correct structural abnormalities in DNA. Homology-mediated or homology-independent gene recovery strategies that require donor DNAs have been developed and widely applied to precisely correct mutated sequences in genes of interest. In contrast to the DNA cleavage-mediated gene correction methods listed above, base-editing tools enable base conversion in the absence of donor DNAs. In addition, CRISPR-associated transposases have been harnessed to generate a targeted knockin, and prime editors have been developed to edit tens of nucleotides in cells. Here, we introduce currently developed gene recovery strategies and discuss the pros and cons of each.

Entities:  

Year:  2020        PMID: 32651459      PMCID: PMC8080666          DOI: 10.1038/s12276-020-0466-1

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  103 in total

1.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.

Authors:  Chengzu Long; John R McAnally; John M Shelton; Alex A Mireault; Rhonda Bassel-Duby; Eric N Olson
Journal:  Science       Date:  2014-08-14       Impact factor: 47.728

Review 2.  The next generation of CRISPR-Cas technologies and applications.

Authors:  Adrian Pickar-Oliver; Charles A Gersbach
Journal:  Nat Rev Mol Cell Biol       Date:  2019-08       Impact factor: 94.444

3.  Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.

Authors:  Calvin J Stephens; Elvin J Lauron; Elena Kashentseva; Zhi Hong Lu; Wayne M Yokoyama; David T Curiel
Journal:  J Control Release       Date:  2019-02-13       Impact factor: 9.776

4.  Correction of a genetic disease in mouse via use of CRISPR-Cas9.

Authors:  Yuxuan Wu; Dan Liang; Yinghua Wang; Meizhu Bai; Wei Tang; Shiming Bao; Zhiqiang Yan; Dangsheng Li; Jinsong Li
Journal:  Cell Stem Cell       Date:  2013-12-05       Impact factor: 24.633

5.  Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors.

Authors:  Sara P Garcia; Sowmya Iyer; Caleb A Lareau; Julian Grünewald; Ronghao Zhou; Martin J Aryee; J Keith Joung
Journal:  Nature       Date:  2019-04-17       Impact factor: 49.962

6.  Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration.

Authors:  Phuc L H Vo; Tyler S Halpin-Healy; Sanne E Klompe; Samuel H Sternberg
Journal:  Nature       Date:  2019-06-12       Impact factor: 49.962

7.  CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.

Authors:  Pei Zhu; Furen Wu; Jeffrey Mosenson; Hongmei Zhang; Tong-Chuan He; Wen-Shu Wu
Journal:  Mol Ther Nucleic Acids       Date:  2017-02-28

8.  Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair.

Authors:  Araksya Izmiryan; Clarisse Ganier; Matteo Bovolenta; Alain Schmitt; Fulvio Mavilio; Alain Hovnanian
Journal:  Mol Ther Nucleic Acids       Date:  2018-06-26       Impact factor: 8.886

9.  Precise therapeutic gene correction by a simple nuclease-induced double-stranded break.

Authors:  Sukanya Iyer; Sneha Suresh; Dongsheng Guo; Katelyn Daman; Jennifer C J Chen; Pengpeng Liu; Marina Zieger; Kevin Luk; Benjamin P Roscoe; Christian Mueller; Oliver D King; Charles P Emerson; Scot A Wolfe
Journal:  Nature       Date:  2019-04-03       Impact factor: 49.962

10.  SpCas9 activity prediction by DeepSpCas9, a deep learning-based model with high generalization performance.

Authors:  Hui Kwon Kim; Younggwang Kim; Sungtae Lee; Seonwoo Min; Jung Yoon Bae; Jae Woo Choi; Jinman Park; Dongmin Jung; Sungroh Yoon; Hyongbum Henry Kim
Journal:  Sci Adv       Date:  2019-11-06       Impact factor: 14.136

View more
  9 in total

1.  Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.

Authors:  Sung-Ah Hong; Song-Ee Kim; A-Young Lee; Gue-Ho Hwang; Jong Hoon Kim; Hiroaki Iwata; Soo-Chan Kim; Sangsu Bae; Sang Eun Lee
Journal:  Mol Ther       Date:  2022-06-10       Impact factor: 12.910

Review 2.  CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.

Authors:  Hanan Bloomer; Jennifer Khirallah; Yamin Li; Qiaobing Xu
Journal:  Adv Drug Deliv Rev       Date:  2021-12-20       Impact factor: 15.470

3.  In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment.

Authors:  Sung-Ah Hong; Jung Hwa Seo; Soohyun Wi; Eul Sik Jung; Jihyeon Yu; Gue-Ho Hwang; Ji Hea Yu; Ahreum Baek; Soeon Park; Sangsu Bae; Sung-Rae Cho
Journal:  Mol Ther       Date:  2021-05-29       Impact factor: 11.454

4.  High-purity production and precise editing of DNA base editing ribonucleoproteins.

Authors:  Hyeon-Ki Jang; Dong Hyun Jo; Seu-Na Lee; Chang Sik Cho; You Kyeong Jeong; Youngri Jung; Jihyeon Yu; Jeong Hun Kim; Jae-Sung Woo; Sangsu Bae
Journal:  Sci Adv       Date:  2021-08-27       Impact factor: 14.136

5.  Modeling of lung phenotype of Hermansky-Pudlak syndrome type I using patient-specific iPSCs.

Authors:  Takahiro Suezawa; Shuhei Kanagaki; Yohei Korogi; Kazuhisa Nakao; Toyohiro Hirai; Koji Murakami; Masatoshi Hagiwara; Shimpei Gotoh
Journal:  Respir Res       Date:  2021-11-04

Review 6.  CRISPR Therapeutics for Duchenne Muscular Dystrophy.

Authors:  Esra Erkut; Toshifumi Yokota
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

7.  Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.

Authors:  Francesca Tasca; Marcella Brescia; Qian Wang; Jin Liu; Josephine M Janssen; Karoly Szuhai; Manuel A F V Gonçalves
Journal:  Nucleic Acids Res       Date:  2022-07-22       Impact factor: 19.160

8.  Analysis of NHEJ-Based DNA Repair after CRISPR-Mediated DNA Cleavage.

Authors:  Beomjong Song; Soyeon Yang; Gue-Ho Hwang; Jihyeon Yu; Sangsu Bae
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 9.  CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria.

Authors:  Dennise Palacios Araya; Kelli L Palmer; Breck A Duerkop
Journal:  PLoS Pathog       Date:  2021-07-08       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.